Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$98.09
+$2.68 · +2.81%
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Previous close
$98.09
+$2.68 · +2.81%
After-hours
$98.09
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Day range
Current $98.09
52-week range
Current $98.09
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
89
Deep Value
Sentiment
51
Mixed
Risk
38
Moderate Risk
Momentum
75
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Day range
Current $98.09
52-week range
Current $98.09
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 305.11M USD | 152.58M USD | 71.73M USD |
| Cost of goods sold | 96.65M USD | 71.67M USD | 54.42M USD |
| Gross profit | 208.46M USD | 80.92M USD | 17.31M USD |
| Research and development | 49.38M USD | 36.6M USD | 22.41M USD |
| Selling, general, and administrative | 143.05M USD | 91.47M USD | 64.39M USD |
| Operating expenses | 192.44M USD | 128.06M USD | 86.8M USD |
| Interest income | 7.75M USD | 5.82M USD | 3.46M USD |
| Interest expense | 95K USD | 2.39M USD | 3.27M USD |
| Depreciation and amortization | 11.91M USD | 11.69M USD | 6.46M USD |
| Operating income | 16.02M USD | −47.15M USD | −69.5M USD |
| Net income | 7.45M USD | −41.57M USD | −82.68M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$126
28.45% upsidePrice history unavailable
High $130Average $126Low $120Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI65.81M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB47.52M0.03%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR15.1M0.02%68.2B USD0.05%$234.43+0.22%
Vanguard Morningstar Small-Cap Growth ETFVBK13.61M0.03%44.7B USD0.05%$344.74+1.22%
Schwab U.S. Small-Cap ETFSCHA11.19M0.05%21.73B USD0.03%$32.79+0.40%
F/M Emerald Life Sciences Innovation ETFLFSC5.3M4.49%115M USD0.79%$42.6071+2.24%
Vanguard Extended Market ETFVXF4.77M0.00%95.4B USD0.05%$235+0.80%
iShares U.S. Healthcare Providers ETFIHF3.7M0.28%1.35B USD0.37%$56.76+1.74%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Morningstar Small-Cap Growth ETFVBKSchwab U.S. Small-Cap ETFSCHAF/M Emerald Life Sciences Innovation ETFLFSCVanguard Extended Market ETFVXFiShares U.S. Healthcare Providers ETFIHFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
